Could a Lead-Clearing drug protect kidneys in diabetes?
NCT ID NCT07706946
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether a drug that removes lead from the blood can slow the worsening of kidney function in people with type 2 diabetes who also have higher-than-normal lead levels. Participants receive intravenous infusions of calcium disodium edetate, and their kidney function is tracked for 12 months. The goal is to see if reducing lead burden helps preserve kidney health in this specific group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a lead-removing drug called calcium disodium edetate, given intravenously
- What this could lead to
- If it works, this could point toward a new way to slow kidney disease in people with diabetes who also have high lead levels.
- What could go wrong
- This is a small, early-stage study with only 42 participants, so results may not apply widely. The treatment involves intravenous infusions and may have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEAD-BURDENED TYPE 2 DIABETIC NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.